Active Not Recruiting PHASE1 INTERVENTIONAL 2-arm NCT06614855

A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma

Sponsor: James Markert, MD

Conditions Astrocytoma Astrocytoma, Grade III Astrocytoma, Grade IV Glioblastoma Glioblastoma (GBM) Gliosarcoma of Brain Gliosarcoma, Adult

Interventions C134

Updated 4 times since 2024 Last updated: Jul 31, 2025 Started: Jun 2, 2025 Primary completion: Jan 1, 2027 Completion: Jan 1, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06614855, this PHASE1 trial focuses on Astrocytoma and Astrocytoma, Grade III and remains ongoing. Sponsored by James Markert, MD, it has been updated 4 times since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE1

Status: Not Yet Recruiting → Active Not Recruiting
Feb 2025 — Sep 2025 [monthly]

Not Yet Recruiting PHASE1
Nov 2024 — Feb 2025 [monthly]

Not Yet Recruiting PHASE1
Oct 2024 — Nov 2024 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

James Markert, MD

Data source: University of Alabama at Birmingham

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Birmingham, United States